Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)41.11
  • Today's Change2.86 / 7.48%
  • Shares traded13.40m
  • 1 Year change-47.41%
  • Beta1.5959
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments8,6049,90210,727
Total Receivables, Net1,0811,6643,296
Total Inventory2029491,441
Prepaid expenses350851531
Other current assets, total886576
Total current assets10,32513,43116,071
Property, plant & equipment, net2,6582,1391,383
Goodwill, net52----
Intangibles, net44----
Long term investments4,7438,3186,843
Note receivable - long term------
Other long term assets17798834
Total assets18,42625,85824,669
LIABILITIES
Accounts payable520487302
Accrued expenses1,8232,1361,518
Notes payable/short-term debt000
Current portion long-term debt/capital leases0161165
Other current liabilities, total6722,1397,143
Total current liabilities3,0154,9239,128
Total long term debt575912599
Total debt5751,073764
Deferred income tax------
Minority interest------
Other liabilities, total982900797
Total liabilities4,5726,73510,524
SHAREHOLDERS EQUITY
Common stock0.040.040
Additional paid-in capital3711,1734,211
Retained earnings (accumulated deficit)13,60618,3209,958
Treasury stock - common------
Unrealized gain (loss)(114)(362)--
Other equity, total(9.04)(8.04)(24)
Total equity13,85419,12314,145
Total liabilities & shareholders' equity18,42625,85824,669
Total common shares outstanding382385403
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.